Skip to main content
. 2023 Feb 8;299(3):102992. doi: 10.1016/j.jbc.2023.102992

Figure 2.

Figure 2

NAV-2729 does not affect the Golgi apparatus but does affect the actin cytoskeleton.A, effect of NAV-2729 and Brefeldin A on RD and U2OS cells. Cells were treated with DMSO, NAV-2729, or Brefeldin A, then stained using DAPI and immunostained for GM130 and β-COP. Scale bars are 25 μm. B, NAV-2729 does not affect the Golgi in RD cells. Surface area and volume of the Golgi in the cells treated as described in (A) were determined using GM130 as a marker. C, NAV-2729 does not affect Arf1•GTP binding to GGA3. myrArf1•GTP binding to the VHS-GAT tandem from GGA3 fused to GST in the presence or absence of 50 μM NAV-2729 was determined. GST was the negative control. Representative experiment of 3 is shown. D, NAV-2729 and Bragsin effects on the actin cytoskeleton. RD and U2OS cells were plated on fibronectin-coated coverslips and treated with either DMSO, NAV-2729, or Bragsin. Cells were immunostained for paxillin and for filamentous actin. Scale bars are 25 μm for all images except the far right images, which are an approximately 2.7-factor zoom of the images for paxillin within the white boxes. The scale bars are 10 μm in length for the zoomed images. Arrows point to example focal adhesions. E, quantification of actin stress fibers (RD and U2OS), focal adhesions (U2OS), and surface area (U2OS) of the cells shown in (D). ∗p < 0.05; ∗∗p < 0.01; ∗∗∗∗p <0.0001. Arf, ADP-ribosylation factor.